依达拉奉对心源性脑栓塞患者T淋巴细胞亚群及氧化应激水平的影响

Effect of Edaravone on the T-lymphocyte Subset and Oxidative Stress Level of Patients with Cardioembolism

目的探究依达拉奉对心源性脑栓塞起患者T淋巴细胞亚群及氧化应激水平的影响。方法将2016年1月—2017年12月在该院接受诊治的90例心源性脑栓塞患者作为该次研究的主要对象,所有患者被随机分配到两组,常规治疗组45例患者采用常规方法进行治疗,研究治疗组45例患者则采用依达拉奉进行治疗,治疗结束后对两组患者的治疗效果、不良反应情况以及各项指标变化情况进行调查。结果在两组患者的治疗效果方面,研究治疗组患者的显效率和总有效率分别达到44.44%和91.11%,治疗无效的患者为4例,治疗无效率为8.89%,常规治疗组患者的显效率和总有效率分别为28.89%和71.11%,治疗无效的患者为13例,治疗无效率高达28.89%,差异有统计学意义(χ~2=5.74,P<0.05)。在不良反应发生情况方面,研究治疗组中心力衰竭患者2例,出血性脑栓塞患者3例,过敏患者3例,不良反应总发生率为17.78%。常规治疗组中心力衰竭患者5例,出血性脑栓塞患者6例,过敏患者8例,不良反应总发生率为42.22%,差异有统计学意义(χ~2=5.82,P<0.05)。在多项指标治疗前后的变化情况方面,两组患者的各项指标经治疗均有不同程度的改善,但研究治疗组患者各项指标的改善幅度更为明显。结论将依达拉奉应用于心源性脑栓塞的临床治疗当中,能够有效改善患者的T淋巴细胞亚群平衡,大幅降低了患者氧化应激水平,效果明显,值得推广。

Objective To study the effect of edaravone on the t-lymphocyte subset and oxidative stress level of patients with cardioembolism. Methods 90 cases of patients with cardioembolism admitted and treated in our hospital from January 2016 to December 2017 were selected and randomly divided into two groups with 45 cases in each, the routine treatment group used the routine method, while the research treatment group were treated with edaravone on the basis of the control group, and the treatment effect, adverse reactions and changes of various indicators of the two groups at the end of treatment were surveyed. Results The markedly effective rate and total effective rate in the research group and in the routine treatment group were respectively 44.44%, 91.11%; 28.89%, 71.11%, and in the research group, 4 cases were ineffective, and the ineffective rate was 8.89%, while in the routine group, 13 cases were ineffective, and the treatment ineffective rate reached 28.89%, and the differences between groups were statistically significant（χ~2=5.74, P0.05）, and in the research group, 2 cases had the heart failure, 3 cases had the cardioembolism, 3 cases were allergy, and the incidence rate of adverse reactions was 17.78%, and in the routine group, 5 cases had the heart failure,6 cases had the cardioembolism, 8 cases were alleary, and the total incidence rate of adverse reactions was 42.22%,and the differences between groups were statistically significant（χ~2=5.82, P 0.05）, and various indicators were improved to a certain degree after treatment, but the improvement range in the research group was more obvious than that in the routine group. Conclusion The application of edaravone in clinical treatment of cardioembolism can effectively improve the balance of t-lymphocyte subsets, and greatly reduce the oxidative stress level, and the effect is obvious,and it is worth promotion.